In ovarian cancer, FDA-approved poly ADP-ribose polymerase inhibitors, olaparib and rucaparib, have been used for the treatment of ovarian cancer in patients harboring the BRCA1, BRCA2, and other DNA repair gene mutations (28) and were sensitive to platinum-based chemotherapies (29). This evidence concerns the gene BRCA1 and ovarian cancer.